Combined photodynamic and antiangiogenic therapy in patients with exudative form of age-related macular degeneration
The paper presents data on the efficacy of combined anti-angiogenic (rvanibizumab) and photodynamic (phthalocyanine) therapy in the treatment of exudative form of AMD. 52 patients (52 eyes) with exudative form of AMD were examined and treated. The control group consisted of 14 people who received the course of antioxidant, neuroprotective therapy. Photosensitizer “Photosense” (aluminum phthalocyanine) was injected intravenously in a dose of 0.05 mg/kg. Irradiation conditions: a session was conducted using a laser wavelength of 675 nm, the light exposure dose of 120 J/cm <sup>2</sup> as monotherapy (18 people), and in combination with intravitreal injections of Lucentis (ranibizumab) (20 members). The largest percentage increase of visual functions can be noted in the group with combination of photodynamic and angiogenic therapy- 50% (10 eyes) by the end of the third month, 75% (15 eyes) in 12 months, 90% (18 eyes) in 24 months. The obtained clinical results demonstrate the eff ectiveness of combination therapy with our native medication “Photosens” and antiangiogenic drug “Lucentis” in the treatment of exudative age-related macular degeneration.